Two or three years ago, people in biotech would have said you were nuts if you had predicted a revival of cancer immunotherapy. Dendreon, the Seattle-based trailblazer, had its well-documented stumbles in the marketplace. But researchers have never been more excited about the various ways of harnessing the immune system to kill cancer cells. Enthusiasm was stirred by a series of groundbreaking presentations at medical meetings in 2013, and one of the richest biotech startup financings in industry history (Seattle-based Juno Therapeutics). Come hear from leading scientists and entrepreneurs from around the country who can candidly discuss the opportunities, and challenges, in this emerging field.